Two Eye Drop Makers Recall Eyedrops - Pharmedica and Apotex - After FDA Warns to Not Use a 3rd Product, Desalm Pharma

Mark Hake

In February 2023 the FDA warned consumers to not use contaminated artificial eyedrops - Delsam Pharma’s Artificial Eye Ointment or EzriCare Artificial Tears. This was due to potential bacterial contamination.

The FDA said that using contaminated artificial tears increases the risk of eye infections that could result in blindness or death.

New Recalls

Now, several months later two other makers are recalling their eyedrops and the FDA issued a recall of their products as well.
Photo byEzricare

They are "Purely Soothing 15% MSM Drops" made by Pharmedia USA LLC, due to non-sterility as well as Brimonidine Tartrate Ophthalmic Solution (0.15%) made by Apotex Corp. The latter products had cracks that developed in some of the caps of the bottles.

“Use of contaminated eye drops can result in the risk of eye infections that could result in blindness,” Pharmedica said about some of its Purely Soothing 15% MSM Drops.

Apotex said that its recall was being initiated out of an abundance of caution due to cracks that have developed in some of the units caps of Brimonidine tartrate ophthalmic solution bottles. The company said that there is a possibility the broken cap may impact sterility and if so, the possibility of adverse events.

This goes to show that people who use eyedrops to liquidate or wet them must use an abundance of caution when they purchase any new batch of even their favorite products.

They should always check online whether there has been a recent recall that may have slipped by store operators taking the products off the shelf.


You can also download the Newsbreak app to become a Registered Follower. That way you can see all my prior articles. Click on the link underneath my profile name above.

Mark R. Hake, CFA, writes articles on national and local news, stocks, and market events at,,, and as well as TalkMarkets.

This is original content from NewsBreak’s Creator Program. Join today to publish and share your own content.

Comments / 7

Published by

Mark Hake is a financial analyst, investor, and Chartered Financial Analyst (CFA). He writes about US and foreign stocks as well as cryptos, hedge funds, and private equity. He previously ran his own hedge fund, investment research firm, and acted as CFO for a fintech startup. He focuses on finding value, arbitrage, and hidden asset opportunities.

Phoenix, AZ

More from Mark Hake

Comments / 0